IDO1 is an Integral Mediator of Inflammatory Neovascularization

EBioMedicine

Volumn 14, Issue , 2016, Pages 74-82

  Mondal, Arpita ^a,b   Smith, Courtney ^a   DuHadaway, James B ^a   Sutanto Ward, Erika ^a   Prendergast, George C ^a,c   Bravo Nuevo, Arturo ^a   Muller, Alexander J ^a,c  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Angiogenesis; Indoleamine 2,3 dioxygenase; Inflammation; Interferon gamma; Interleukin 6; Lung metastasis; Oxygen induced retinopathy; Tryptophan

Indexed keywords

CYCLOPHOSPHAMIDE; EPACADOSTAT; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; SMALL INTERFERING RNA; VASCULOTROPIN A; AUTACOID; CYTOKINE; IDO1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE LOSS; HYPEROXIA; IMMUNOFLUORESCENCE; LUNG METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NEWBORN; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; VITREOUS BODY; ANIMAL; COMPLICATION; DISEASE MODEL; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; METASTASIS; NEOPLASMS; PATHOLOGY;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; INFLAMMATION MEDIATORS; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 85004093150     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.11.013     Document Type: Article

References (33)

1. Aslakson, C.J., Miller, F.R., Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52 (1992), 1399–1405.
2. Beatty, G.L., Paterson, Y., Regulation of tumor growth by IFN-gamma in cancer immunotherapy. Immunol. Res. 24 (2001), 201–210.
3. Blaschitz, A., Gauster, M., Fuchs, D., Lang, I., Maschke, P., Ulrich, D., Karpf, E., Takikawa, O., Schimek, M.G., Dohr, G., Sedlmayr, P., Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS One, 6, 2011, e21774.
4. Bocci, G., Nicolaou, K.C., Kerbel, R.S., Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62 (2002), 6938–6943.
5. Cao, Y., Arbiser, J., D'amato, R.J., D'amore, P.A., Ingber, D.E., Kerbel, R., Klagsbrun, M., Lim, S., Moses, M.A., Zetter, B., Dvorak, H., Langer, R., Forty-year journey of angiogenesis translational research. Sci. Transl. Med., 3, 2011, 114rv3.
6. Carmeliet, P., Angiogenesis in health and disease. Nat. Med. 9 (2003), 653–660.
7. Connor, K.M., Krah, N.M., Dennison, R.J., Aderman, C.M., Chen, J., Guerin, K.I., Sapieha, P., Stahl, A., Willett, K.L., Smith, L.E., Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc. 4 (2009), 1565–1573.
8. Dinatale, B.C., Murray, I.A., Schroeder, J.C., Flaveny, C.A., Lahoti, T.S., Laurenzana, E.M., Omiecinski, C.J., Perdew, G.H., Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 115 (2010), 89–97.
9. Holtan, S.G., Creedon, D.J., Mother knows best: lessons from fetomaternal tolerance applied to cancer immunity. Front. Biosci. (Schol. Ed.) 3 (2011), 1533–1540.
10. Hou, D.Y., Muller, A.J., Sharma, M.D., DuHadaway, J., Banerjee, T., Johnson, M., Mellor, A.L., Prendergast, G.C., Munn, D.H., Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67 (2007), 792–801.
11. Ibe, S., Qin, Z., Schuler, T., Preiss, S., Blankenstein, T., Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med. 194 (2001), 1549–1559.
12. Lee, Y.M., Kim, J., Jo, K., Shin, S.D., Kim, C.S., Sohn, E.J., Kim, S.G., Kim, J.S., Ethyl pyruvate inhibits retinal pathogenic neovascularization by downregulating HMGB1 expression. J. Diabetes Res., 2013, 2013, 245271.
13. Li, Y., Tredget, E.E., Ghaffari, A., Lin, X., Kilani, R.T., Ghahary, A., Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J. Invest. Dermatol. 126 (2006), 128–136.
14. Liu, X., Shin, N., Koblish, H.K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M.J., Thomas, B., Rupar, M., Waeltz, P., Bowman, K.J., Polam, P., Sparks, R.B., Yue, E.W., Li, Y., Wynn, R., Fridman, J.S., Burn, T.C., Combs, A.P., Newton, R.C., Scherle, P.A., Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115 (2010), 3520–3530.
15. Liu, H., Huang, L., Bradley, J., Liu, K., Bardhan, K., Ron, D., Mellor, A.L., Munn, D.H., Mcgaha, T.L., GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology. Mol. Cell. Biol. 34 (2014), 428–438.
16. Metz, R., Smith, C., DuHadaway, J.B., Chandler, P., Baban, B., Merlo, L.M., Pigott, E., Keough, M.P., Rust, S., Mellor, A.L., Mandik-Nayak, L., Muller, A.J., Prendergast, G.C., IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int. Immunol. 26 (2014), 357–367.
17. Middleton, K., Jones, J., Lwin, Z., Coward, J.I., Interleukin-6: an angiogenic target in solid tumours. Crit. Rev. Oncol. Hematol. 89 (2014), 129–139.
18. Muller, A.J., DuHadaway, J.B., Donover, P.S., Sutanto-Ward, E., Prendergast, G.C., Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11 (2005), 312–319.
19. Muller, A.J., Sharma, M.D., Chandler, P.R., DuHadaway, J.B., Everhart, M.E., Johnson, B.A. 3rd, Kahler, D.J., Pihkala, J., Soler, A.P., Munn, D.H., Prendergast, G.C., Mellor, A.L., Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 17073–17078.
20. Muller, A.J., DuHadaway, J.B., Jaller, D., Curtis, P., Metz, R., Prendergast, G.C., Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res. 70 (2010), 1845–1853.
21. Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I., Conway, S.J., Marshall, B., Brown, C., Mellor, A.L., Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998), 1191–1193.
22. Munn, D.H., Shafizadeh, E., Attwood, J.T., Bondarev, I., Pashine, A., Mellor, A.L., Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189 (1999), 1363–1372.
23. Munn, D.H., Sharma, M.D., Hou, D., Baban, B., Lee, J.R., Antonia, S.J., Messina, J.L., Chandler, P., Koni, P.A., Mellor, A.L., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114 (2004), 280–290.
24. Nonaka, H., Saga, Y., Fujiwara, H., Akimoto, H., Yamada, A., Kagawa, S., Takei, Y., Machida, S., Takikawa, O., Suzuki, M., Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion. Int. J. Oncol. 38 (2011), 113–120.
25. Palmer, G.M., Tiran, Z., Zhou, Z., Capozzi, M.E., Park, W., Coletta, C., Pyriochou, A., Kliger, Y., Levy, O., Borukhov, I., Dewhirst, M.W., Rotman, G., Penn, J.S., Papapetropoulos, A., A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization. Br. J. Pharmacol. 165 (2012), 1891–1903.
26. PEEK, R.M. JR., Mohla, S., Dubois, R.N., Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res. 65 (2005), 8583–8586.
27. Qin, Z., Blankenstein, T., CD4 + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12 (2000), 677–686.
28. Qin, Z., Schwartzkopff, J., Pradera, F., Kammertoens, T., Seliger, B., Pircher, H., Blankenstein, T., A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8 + T cells. Cancer Res. 63 (2003), 4095–4100.
29. Smith, C., Chang, M.Y., Parker, K.H., Beury, D.W., DuHadaway, J.B., Flick, H.E., Boulden, J., Sutanto-Ward, E., Soler, A.P., Laury-Kleintop, L.D., Mandik-Nayak, L., Metz, R., Ostrand-Rosenberg, S., Prendergast, G.C., Muller, A.J., IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2 (2012), 722–735.
30. Soliman, H.H., Minton, S.E., Han, H.S., Ismail-Khan, R., Mahipal, A., Janssen, W., Streicher, H., Vahanian, N.N., Link, C.J., Ramsey, W.J., Antonia, S.J., Sullivan, D., A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. 2013 ASCO Annual Meeting, 2013, J. Clin. Oncol, Chicago, IL.
31. Stahl, A., Joyal, J.S., Chen, J., Sapieha, P., Juan, A.M., Hatton, C.J., Pei, D.T., Hurst, C.G., Seaward, M.R., Krah, N.M., Dennison, R.J., Greene, E.R., Boscolo, E., Panigrahy, D., Smith, L.E., SOCS3 is an endogenous inhibitor of pathologic angiogenesis. Blood 120 (2012), 2925–2929.
32. Taylor, M.W., Feng, G.S., Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5 (1991), 2516–2522.
33. Triantafylla, M., Massa, H.F., Dardabounis, D., Gatzioufas, Z., Kozobolis, V., Ioannakis, K., Perente, I., Panos, G.D., Ranibizumab for the treatment of degenerative ocular conditions. Clin. Ophthalmol. 8 (2014), 1187–1198.